PMID- 38458429
OWN - NLM
STAT- Publisher
LR  - 20240401
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
DP  - 2024 Mar 6
TI  - Tumor-Intrinsic Galectin-3 Suppresses Melanoma Metastasis.
LID - S0022-202X(24)00169-6 [pii]
LID - 10.1016/j.jid.2024.02.011 [doi]
AB  - Melanoma poses a poor prognosis with high mortality rates upon metastasis. 
      Exploring the molecular mechanisms governing melanoma progression paves the way 
      for developing novel approaches to control melanoma metastasis and ultimately 
      enhance patient survival rates. Extracellular galectin-3 (Gal-3) has emerged as a 
      pleiotropic promoter of melanoma metastasis, exerting varying activities 
      depending on its interacting partner. However, whether intracellular Gal-3 
      promotes melanoma aggressive behavior remains unknown. In this study, we explored 
      Gal-3 expression in human melanoma tissues as well as in murine melanoma models 
      to examine its causal role in metastatic behavior. We found that Gal-3 expression 
      is downregulated in metastatic melanoma tissues compared with its levels in 
      primary melanomas. Enforced silencing of Gal-3 in melanoma cells promoted 
      migration, invasion, colony formation, in vivo xenograft growth, and metastasis 
      and activated canonical oncogenic signaling pathways. Moreover, loss of Gal-3 in 
      melanoma cells resulted in upregulated the expression of the prometastatic 
      transcription factor NFAT1 and its downstream metastasis-associated proteins, 
      matrix metalloproteinase 3, and IL-8. Overall, our findings implicate melanoma 
      intracellular Gal-3 as a major determinant of its metastatic behavior and reveal 
      a negative regulatory role for Gal-3 on the expression of NFAT1 in melanoma 
      cells.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Mohammed, Norhan B B
AU  - Mohammed NBB
AD  - Translational Glycobiology Institute at FIU, Department of Translational 
      Medicine, Herbert Wertheim College of Medicine, Florida International University, 
      Miami, Florida, USA; Department of Medical Biochemistry, Faculty of Medicine, 
      South Valley University, Qena, Egypt.
FAU - Lau, Lee Seng
AU  - Lau LS
AD  - Translational Glycobiology Institute at FIU, Department of Translational 
      Medicine, Herbert Wertheim College of Medicine, Florida International University, 
      Miami, Florida, USA.
FAU - Souchak, Joseph
AU  - Souchak J
AD  - Translational Glycobiology Institute at FIU, Department of Translational 
      Medicine, Herbert Wertheim College of Medicine, Florida International University, 
      Miami, Florida, USA.
FAU - Qiu, Shi
AU  - Qiu S
AD  - The Ronald O. Perelman Department of Dermatology, NYU Grossman School of 
      Medicine, New York, New York, USA.
FAU - Ahluwalia, Manmeet S
AU  - Ahluwalia MS
AD  - Translational Glycobiology Institute at FIU, Department of Translational 
      Medicine, Herbert Wertheim College of Medicine, Florida International University, 
      Miami, Florida, USA; Department of Medical Oncology, Miami Cancer Institute, 
      Baptist Health-South Florida, Miami, Florida, USA.
FAU - Osman, Iman
AU  - Osman I
AD  - The Ronald O. Perelman Department of Dermatology, NYU Grossman School of 
      Medicine, New York, New York, USA.
FAU - Dimitroff, Charles J
AU  - Dimitroff CJ
AD  - Translational Glycobiology Institute at FIU, Department of Translational 
      Medicine, Herbert Wertheim College of Medicine, Florida International University, 
      Miami, Florida, USA. Electronic address: cdimitroff@fiu.edu.
LA  - eng
GR  - P50 CA225450/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20240306
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
SB  - IM
OTO - NOTNLM
OT  - Galectin-3
OT  - Melanoma
OT  - Metastasis
OT  - NFAT1
OT  - Tumor progression
EDAT- 2024/03/09 10:42
MHDA- 2024/03/09 10:42
CRDT- 2024/03/08 19:16
PHST- 2023/10/23 00:00 [received]
PHST- 2024/01/24 00:00 [revised]
PHST- 2024/02/03 00:00 [accepted]
PHST- 2024/03/09 10:42 [pubmed]
PHST- 2024/03/09 10:42 [medline]
PHST- 2024/03/08 19:16 [entrez]
AID - S0022-202X(24)00169-6 [pii]
AID - 10.1016/j.jid.2024.02.011 [doi]
PST - aheadofprint
SO  - J Invest Dermatol. 2024 Mar 6:S0022-202X(24)00169-6. doi: 
      10.1016/j.jid.2024.02.011.